Log in

NASDAQ:PRTO - Proteon Therapeutics Stock Price, Forecast & News

+0.98 (+2.66 %)
(As of 02/20/2020 02:59 AM ET)
Today's Range
Now: $37.85
50-Day Range
MA: $26.09
52-Week Range
Now: $37.85
Volume15,109 shs
Average Volume1.11 million shs
Market Capitalization$839.48 million
P/E RatioN/A
Dividend YieldN/A
Proteon Therapeutics, Inc, a late-stage biopharmaceutical company, focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. Its lead product candidate is vonapanitase, an investigational drug intended to enhance hemodialysis vascular access outcomes. The company develops vonapanitase, a recombinant human elastase, which has completed Phase II and Phase III clinical trials for patients with chronic kidney disease. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Current SymbolNASDAQ:PRTO



Sales & Book Value

Annual SalesN/A
Book Value($0.06) per share


Net Income$-20,730,000.00


Market Cap$839.48 million
Next Earnings Date3/11/2020 (Estimated)
OptionableNot Optionable

Receive PRTO News and Ratings via Email

Sign-up to receive the latest news and ratings for PRTO and its competitors with MarketBeat's FREE daily newsletter.

Proteon Therapeutics (NASDAQ:PRTO) Frequently Asked Questions

What is Proteon Therapeutics' stock symbol?

Proteon Therapeutics trades on the NASDAQ under the ticker symbol "PRTO."

How were Proteon Therapeutics' earnings last quarter?

Proteon Therapeutics Inc (NASDAQ:PRTO) issued its quarterly earnings data on Thursday, October, 31st. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, topping analysts' consensus estimates of ($0.09) by $0.01. View Proteon Therapeutics' Earnings History.

When is Proteon Therapeutics' next earnings date?

Proteon Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, March 11th 2020. View Earnings Estimates for Proteon Therapeutics.

What price target have analysts set for PRTO?

5 brokers have issued 12-month price objectives for Proteon Therapeutics' stock. Their forecasts range from $1.00 to $5.00. On average, they expect Proteon Therapeutics' share price to reach $3.33 in the next twelve months. This suggests that the stock has a possible downside of 91.2%. View Analyst Price Targets for Proteon Therapeutics.

What is the consensus analysts' recommendation for Proteon Therapeutics?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Proteon Therapeutics in the last year. There are currently 4 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Proteon Therapeutics.

What are Wall Street analysts saying about Proteon Therapeutics stock?

Here are some recent quotes from research analysts about Proteon Therapeutics stock:
  • 1. According to Zacks Investment Research, "Proteon Therapeutics Inc. is a biopharmaceutical company. The Company is developing pharmaceuticals to address the medical needs of patients with kidney and vascular diseases. It is developing PRT-201, a recombinant human elastase, applied in a single treatment to the external surface of arteries and veins during an open surgical procedure or an endovascular intervention. Proteon Therapeutics Inc. is headquartered in Waltham, Mass. " (11/14/2019)
  • 2. Maxim Group analysts commented, "Proteon announced that the second phase 3 study of vonapanitase failed to reach statistical significance on both co-primary endpoints; secondary patency and fistula use for hemodialysis. The company is evaluating its strategic options and has $16.5M in cash on the balance sheet. Shares are down sharply (~83%). We have removed vonapanitase from our model and are downgrading the shares to and removing our prior price target of $5.00 as the company explores its options." (3/28/2019)

Has Proteon Therapeutics been receiving favorable news coverage?

Media stories about PRTO stock have trended positive recently, InfoTrie Sentiment reports. The research group scores the sentiment of media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Proteon Therapeutics earned a media sentiment score of 3.0 on InfoTrie's scale. They also assigned news coverage about the biopharmaceutical company a news buzz of 1.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for Proteon Therapeutics.

Are investors shorting Proteon Therapeutics?

Proteon Therapeutics saw a drop in short interest during the month of January. As of January 15th, there was short interest totalling 58,500 shares, a drop of 52.6% from the December 31st total of 123,400 shares. Based on an average trading volume of 7,400 shares, the short-interest ratio is presently 7.9 days. Approximately 20.1% of the company's shares are sold short. View Proteon Therapeutics' Current Options Chain.

Who are some of Proteon Therapeutics' key competitors?

What other stocks do shareholders of Proteon Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Proteon Therapeutics investors own include Celgene (CELG), SCYNEXIS (SCYX), Synergy Pharmaceuticals (SGYP), Sierra Oncology (SRRA), Verastem (VSTM), vTv Therapeutics (VTVT), Agile Therapeutics (AGRX), Biocept (BIOC), Fate Therapeutics (FATE) and Idera Pharmaceuticals (IDRA).

Who are Proteon Therapeutics' key executives?

Proteon Therapeutics' management team includes the folowing people:
  • Mr. Timothy P. Noyes, Pres, CEO & Director (Age 57)
  • Mr. George A. Eldridge, Sr. VP, CFO, Treasurer & Assistant Sec. (Age 56)
  • Dr. Steven Keith Burke, Sr. VP & Chief Medical Officer (Age 58)
  • Mr. Matthew P. Kowalsky, VP of Legal & Sec. (Age 46)
  • Mr. Bradley J. Hartman, VP of People (Age 38)

Who are Proteon Therapeutics' major shareholders?

Proteon Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Abingworth LLP (9.67%), Renaissance Technologies LLC (3.81%), Perceptive Advisors LLC (1.54%), Fairmount Funds Management LLC (1.54%), Perceptive Advisors LLC (1.54%) and Ikarian Capital LLC (1.52%). View Institutional Ownership Trends for Proteon Therapeutics.

Which institutional investors are selling Proteon Therapeutics stock?

PRTO stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG. View Insider Buying and Selling for Proteon Therapeutics.

Which institutional investors are buying Proteon Therapeutics stock?

PRTO stock was acquired by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Perceptive Advisors LLC, Fairmount Funds Management LLC, Ikarian Capital LLC, Abingworth LLP, Renaissance Technologies LLC and Wedbush Securities Inc.. View Insider Buying and Selling for Proteon Therapeutics.

How do I buy shares of Proteon Therapeutics?

Shares of PRTO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Proteon Therapeutics' stock price today?

One share of PRTO stock can currently be purchased for approximately $37.85.

How big of a company is Proteon Therapeutics?

Proteon Therapeutics has a market capitalization of $839.48 million. The biopharmaceutical company earns $-20,730,000.00 in net income (profit) each year or ($1.15) on an earnings per share basis. Proteon Therapeutics employs 17 workers across the globe.View Additional Information About Proteon Therapeutics.

What is Proteon Therapeutics' official website?

The official website for Proteon Therapeutics is http://www.proteontherapeutics.com/.

How can I contact Proteon Therapeutics?

Proteon Therapeutics' mailing address is 200 WEST STREET, WALTHAM MA, 02451. The biopharmaceutical company can be reached via phone at 781-890-0102 or via email at [email protected]

MarketBeat Community Rating for Proteon Therapeutics (NASDAQ PRTO)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  267 (Vote Outperform)
Underperform Votes:  239 (Vote Underperform)
Total Votes:  506
MarketBeat's community ratings are surveys of what our community members think about Proteon Therapeutics and other stocks. Vote "Outperform" if you believe PRTO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PRTO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/20/2020 by MarketBeat.com Staff

Featured Article: Resistance Level

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel